Re-directed T cell therapy in dogs with B cell lymphoma
Summary: This study will investigate the use of a state-of-the-art genetic approach to generate anti-tumor immune responses that will kill tumor cells and prevent tumor recurrence in dogs with B cell lymphoma.
Description: White blood cells known as T lymphocytes are part of the immune system and play an important role in recognizing and killing tumors. In patients with cancer the number and function of these cells is impaired allowing tumors to grow and spread. In this study we aim to genetically modify canine T lymphocytes so that we can generate large numbers that are highly functional and specifically recognize and kill tumor cells. In the first part of the study we will investigate ways to optimize gene transfer into dog T lymphocytes and demonstrate the ability of these genetically modified cells to kill target cells in the laboratory. In the second part of this study, we will perform a phase I clinical trial in client owned dogs with relapsed, refractory B cell lymphoma to determine whether genetically modified T lymphocytes given back to the patient expand, persist and kill tumor. If successful, this approach should lead to tumor regression and persistent remission in dogs with B cell lymphoma.
STUDY ID: D13CA-504
INVESTIGATOR: Dr. Nicola J. Mason, University of Pennsylvania